<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069858</url>
  </required_header>
  <id_info>
    <org_study_id>2106AS0033</org_study_id>
    <nct_id>NCT04069858</nct_id>
  </id_info>
  <brief_title>Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B</brief_title>
  <official_title>Maintaining Antiviral Efficacy After Switching to Generic Entecavir, Baracle® in Patients Taking Baraclude® 1 mg for Antiviral Resistant Chronic Hepatitis B; A Noninferiority Study Assessing Non-detection Rate of Hepatitis B Virus DNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Entecavir 1 mg is commonly used in patients with chronic hepatitis B (CHB) patients with
      previous antiviral resistance. This study evaluates the efficacy and safety of switching to
      generic entecavir 1 mg (Baracle®, Dong-A Science Technology) in CHB patients taking brand
      name entecavir 1 mg (Baraclude®, Bristol-Myers Squibb) alone or in combination with other
      nucleos(t)ide analogues after the development of antiviral resistance.

      The primary aim is virological response (&lt;20 IU/mL) at 12 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective single-arm open-label trial. The primary endpoint is virological
      response (&lt;20 IU/mL) at 12 months after switching treatment.

      Patients who satisfy the inclusion and exclusion criteria will switch from Baraclude® 1 mg to
      Baracle®. Assessment of treatment response at 12 months is performed by comparing
      undetectable HBV DNA rates between baseline and 12 months after switching therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>CHB patients receiving treatment with Baraclude® 1 mg alone or in combination with other nucleos(t)ide analogues for 12 months or longer after the development of antiviral resistance.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-detection rate of hepatitis B virus DNA</measure>
    <time_frame>12 months</time_frame>
    <description>undetectable HBV DNA (&lt;20 IU/mL) at 12 months after switching treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of liver enzyme</measure>
    <time_frame>12 months</time_frame>
    <description>ALT &lt; 40 IU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of serological markers of hepatitis B e antigen</measure>
    <time_frame>12 months</time_frame>
    <description>Loss of HBeAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs of newly developing antiviral resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Elevation of hepatitis B virus DNA by 10 fold assessed by real time PCR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Baracle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic hepatitis B patients who swiched to Baracle® 1 mg from Baraclude® 1 mg treatment as mono- or combination therapy after the development of antiviral resistance to nucleos(t)ide analogues</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switching to Generic Entecavir (Baracle®)</intervention_name>
    <description>switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)</description>
    <arm_group_label>Baracle</arm_group_label>
    <other_name>Antiviral therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;19 years old CHB patients

          -  Confirmed antiviral resistance

          -  Taking brand entecavir 1 mg for more than 1 year

          -  HBV DNA &lt; 20 IU/mL

          -  Compensated liver cirrhosis

          -  Willing to participate

        Exclusion Criteria:

          -  Failure to meet the inclusion criteria

          -  Cr&gt;1.5 mg/dL

          -  Postive HCV Ab

          -  Decompensated cirrhosis

          -  Pregnant women

          -  HCC

          -  Alcoholics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung Joon Yim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.</citation>
    <PMID>28427875</PMID>
  </reference>
  <reference>
    <citation>Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.</citation>
    <PMID>29405329</PMID>
  </reference>
  <reference>
    <citation>Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019 Jun;25(2):93-159. doi: 10.3350/cmh.2019.1002. Epub 2019 Jun 12. Review.</citation>
    <PMID>31185710</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hyung Joon Yim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

